CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 20 enrolled
Drug / intervention
Duloxetinedrug
Likely dose
Duloxetine 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00989157
NCT00989157Phase 3Completed

A Preliminary Comparison of the Effect of Roux-en-Y Bariatric Surgery on Blood Levels of Duloxetine

Neuropsychiatric Research Institute, Fargo, North Dakota·interventional·Posted Oct 2, 2009·Updated Aug 11, 2014

In Brief

A Phase 3 clinical trial evaluating Duloxetine for Bariatric Surgery. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This study aims to determine the difference, if any, in the pharmacokinetics of duloxetine between patients who are nine to fifteen months post Roux-en-Y Bariatric Surgery and control subjects matched for body mass index (BMI), age and gender.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2, 2009
Enrollment StartSep 1, 2009
Primary CompletionOct 1, 2012
Study CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 16.8 years ago

Interventions

Duloxetinedrug

Single dose of 60 mg of duloxetine